Christine Eischen Receives AACR-Bayer Innovation and Discovery Grant

17
Nov

Christine Eischen headshotChristine M. Eischen, PhD, Co-Leader of the Molecular Biology & Genetics Program at the Sidney Kimmel Cancer Center at Jefferson, has been awarded a 2017 AACR-Bayer Innovation and Discovery Grant. Her grant is entitled, “Using PROTACS to target the Mdm2 oncoprotein.”

The Innovation and Discovery Grant offers one-year grants to “meritorious projects that examine important, and druggable, novel targets and biomarkers.” The grant partnership, funded by the American Association for Cancer Research (AACR) and Bayer, “will promote the key tenets of the Bayer Grants4Targets™ Initiative, providing new treatment options for cancers with high unmet medical need, encouraging innovation and translation of ideas from basic research into novel drugs, and fostering collaborations between excellent academic groups and the pharmaceutical industry.”

Eischen, who is also a professor and vice chair of the Department of Cancer Biology at Thomas Jefferson University, formally accepted the grant at the AACR Annual Meeting in Chicago, which was held April 14-18, 2018.